13 
Dr. Holmes moved to add current prohibition I-D-4 ("Deliberate release into the 
environment of any organism containing reccrobinant DNA.") to the admonitions 
regarding cloning of toxins and transfer of drug resistance traits. Dr. Landy 
supported inclusion of I-D-4; Dr. Bems did not support it. The motion failed 
to carry by a vote of eight in favor, ten exposed, and two absentions. 
Dr. Baltimore's amended motion was reviewed. Dr. Talbot said that if the pro- 
posal passed, the NIH staff would prepare a version of proposed revised Guide- 
lines based on the proposal, and that it would be put in the Federal Register 
for public comment, along with background describing the work of the working 
group and the deliberations of the RAC. NIH would actively solicit comment on 
the proposal beyond its publication in the Federal Register . 
The question was called and the vote to substitute Dr. Baltimore's motion, as 
amended, for Dr. Harris' motion was fifteen in favor, three exposed, 
and two abstentions. Dr. Ahmed asked to be recorded as voting against the 
motion. The motion was as follows: 
"1. Section I-A of the Guidelines would be amended to read as follows; 
"I-A. Purpose. The purx»se of these Guidelines is to specify standard 
practices for constructing and handling (i) recombinant DNA molecules 
and (ii) organisms and viruses containing recombinant EWA molecules. 
Adherence to these standards by all laboratories using recombinant DNA 
is recommended. 
"2. Section I-C of the Guidelines would be eliminated. 
"3. Section I-D of the Guidelines, Prohibitions , would be eliminated. 
"4. Part III of the Guidelines would be replaced with the following language; 
"Part III discusses experiments covered by the Guidelines. The reader 
should first consult Part I, vhere exempt experiments are listed. 
"Where recommended physical containment levels applicable to non- 
recombinant DNA experiments exist for either the host or the vector*, 
recombinant I»1A experiments should be carried out at containment 
levels at least as high as those recommended for non-recombinant KQA 
experiments. If there is clear evidence that the donor ENA will 
significantly change the pathogenicity of the host, the containment 
level appropriate to the anticipated change will be applied. Other- 
wise, all experiments may be carried out under conditions of Pi or 
Pl-LS physical containment. 
*Such as those specified by the CDC Guidelines or the USDA Quarantine Regulations. 
[204] 
